Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

ClinicalTrials.gov ID: NCT01903291

Public ClinicalTrials.gov record NCT01903291. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with relapsing forms of multiple sclerosis (MS) who are treated with dimethyl fumarate (DMF) after suboptimal response to glatiramer acetate (GA). The secondary objectives of this study in this study population are to assess the impact of DMF over a 12-month period on patient-reported outcomes (PROs) and health economic-related outcomes and to evaluate additional clinical outcomes at Month 12.

Study identification

NCT ID
NCT01903291
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Lead sponsor
Biogen
Industry
Enrollment
333 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2013
Primary completion
Jan 31, 2016
Completion
Jan 31, 2016
Last update posted
Jul 24, 2016

2013 – 2016

United States locations

U.S. sites
62
U.S. states
32
U.S. cities
60
Facility City State ZIP Site status
Research Site Birmingham Alabama 35209
Research Site Tuscon Arizona 85741-1196
Research Site Los Angeles California 90015
Research Site Sacramento California 95816
Research Site San Jose California 95124
Research Site Englewood Colorado 80113
Research Site Dover Delaware 19901
Research Site Jacksonville Florida 32209
Research Site Lighthouse PT Florida 33064
Research Site Port Charlotte Florida 33952
Research Site St. Petersburg Florida 33705
Research Site Tampa Florida 33612
Research Site Atlanta Georgia 30309
Research Site Atlanta Georgia 30327
Research Site Savannah Georgia 31405
Research Site Chicago Illinois 60637-1463
Research Site Evanston Illinois 60201
Research Site Franklin Illinois 37064
Research Site Indianapolis Indiana 46256
Research Site Des Moines Iowa 50314
Research Site Lenexa Kansas 66214-9836
Research Site Lexington Kentucky 40513
Research Site Louisville Kentucky 40207
Research Site Baton Rouge Louisiana 70810-1686
Research Site Annapolis Maryland 21401
Research Site Baltimore Maryland 21201
Research Site Lexington Massachusetts 02421
Research Site Springfield Massachusetts 01104
Research Site Worcester Massachusetts 01655
Research Site Clinton Township Michigan 48035
Research Site Muskegon Michigan 49444-3719
Research Site Golden Valley Minnesota 55422
Research Site Columbia Missouri 65201
Research Site Great Falls Montana 59405
Research Site Lincoln Nebraska 68506-2960
Research Site Lincoln Nebraska 68521
Research Site Omaha Nebraska 68198
Research Site Freehold New Jersey 07728
Research Site New York New York 10032
Research Site Patchogue New York 11772
Research Site The Bronx New York 10467
Research Site Asheville North Carolina 28806
Research Site Hickory North Carolina 28602
Research Site Raleigh North Carolina 27607-6010
Research Site Akron Ohio 44302
Research Site Canton Ohio 44718
Research Site Centerville Ohio 45459
Research Site Columbus Ohio 43221
Research Site Medford Oregon 97504
Research Site Portland Oregon 97225
Research Site Abington Pennsylvania 19001
Research Site Greensburg Pennsylvania 15601
Research Site Pittsburgh Pennsylvania 15212
Research Site Knoxville Tennessee 37934
Research Site Round Rock Texas 78681
Research Site Salt Lake City Utah 84103
Research Site Norfolk Virginia 23502
Research Site Richmond Virginia 23226
Research Site Bellingham Washington 98225
Research Site Seattle Washington 98122
Research Site Tacoma Washington 98405
Research Site Neenah Wisconsin 54946

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01903291, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 24, 2016 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01903291 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →